Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 9, 2007, Pages 1784-1794

  Hong, Chi Chen ^a   Ambrosone, Christine B ^a   Ahn, Jiyoung ^b   Choi, Ji Yeob ^a   McCullough, Marjorie L ^c   Stevens, Victoria L ^c   Rodriguez, Carmen ^c   Thun, Michael J ^c   Calle, Eugenia E ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Division of Cancer Epidemiology and Genetics   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; IRON; NQO1 ENZYME; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRON INTAKE; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEME OXYGENASE-1; HUMANS; IRON; LOGISTIC MODELS; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RISK; RISK FACTORS; SIGNAL TRANSDUCTION; UNITED STATES;

EID: 34548825643     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0247     Document Type: Article

References (106)

1. Nowell SA, Ahn J, Ambrosone CB. Gene-nutrient interactions in cancer etiology. Nutr Rev 2004;62:427-38.
2. Ambrosone CB. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000;2:903-17.
3. Ravn-Haren G, Olsen A, Tjonneland A, et al. Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis 2006;27:820-5.
4. Cai Q, Shu XO, Wen W, et al. Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Breast Cancer Res 2004;6:R647-55.
5. Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA, Hunter DJ. Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:989-96.
6. Ahn J, Gammon MD, Santella RM, et al. Myeloperoxidase genotype, fruit and vegetable consumption and breast cancer risk. Cancer Res 2004;64:7634-9.
7. Ahn J, Gammon MD, Santella RM, et al. Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. Am J Epidemiol 2005;162:943-52.
8. Cade JE, Moreton JA, O'Hara B, et al. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr 2005;82:813-20.
9. Reddy MB, Clark L. Iron, oxidative stress, and disease risk. Nutr Rev 2004;62:120-4.
10. Welch KD, Davis TZ, Van Eden ME, Aust SD. Deleterious ironmediated oxidation of biomolecules. Free Radic Biol Med 2002;32:577-83.
11. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003;533:153-71.
12. Liehr JG, Jones JS. Role of iron in estrogen-induced cancer. Curr Med Chem 2001;8:839-49.
13. Weinstein RE, Bond BH, Silberberg BK. Tissue ferritin concentration in carcinoma of the breast. Cancer 1982;50:2406-9.
14. Elliott RL, Elliott MC, Wang F, Head JF. Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Ann N Y Acad Sci 1993;698:159-66.
15. Thompson HJ, Kennedy K, Witt M, Juzefyk J. Effect of dietary iron deficiency or excess on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis 1991;12:111-4.
16. Hrabinski D, Hertz JL, Tantillo C, Berger V, Sherman AR. Iron repletion attenuates the protective effects of iron deficiency in DMBA-induced mammary tumors in rats. Nutr Cancer 1995;24:133-42.
17. Knekt P, Reunanen A, Takkunen H, et al. Body iron stores and risk of cancer. Int J Cancer 1994;56:379-82.
18. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-9.
19. van Asperen IA, Feskens EJ, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995;24:665-70.
20. Nelson RL. Iron and colorectal cancer risk: human studies. Nutr Rev 2001;59:140-8.
21. Hoshuyama T, Pan G, Tanaka C, et al. Mortality of iron-steel workers in Anshan, China: a retrospective cohort study. Int J Occup Environ Health 2006;12:193-202.
22. Zhou W, Park S, Liu G, et al. Dietary iron, zinc, and calcium and the risk of lungcancer. Epidemiology 2005;16:772-9.
23. Senesse P, Meance S, Cottet V, Faivre J, Boutron-Ruault MC. High dietary iron and copper and risk of colorectal cancer: a case-control study in Burgundy, France. Nutr Cancer 2004;49:66-71.
24. Hercberg S, Estaquio C, Czernichow S, et al. Iron status and risk of cancers in the SU.VI.MAX cohort. J Nutr 2005;135:2664-8.
25. Adzersen KH, Jess P, Freivogel KW, Gerhard I, Bastert G. Raw and cooked vegetables, fruits, selected micronutrients, and breast cancer risk: a case-control study in Germany. Nutr Cancer 2003;46:131-7.
26. Fleming DJ, Tucker KL, Jacques PF, et al. Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr 2002;76:1375-84.
27. Wyllie S, Liehr JG. Release of iron from ferritin storage by redox cyclingof stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen. Arch Biochem Biophys 1997;346:180-6.
28. Roy D, Liehr JG. Temporary decrease in renal quinone reductase activity induced by chronic administration of estradiol to male Syrian hamsters. Increased superoxide formation by redox cyclingof estrogen. J Biol Chem 1988;263:3646-51.
29. Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Mol Endocrinol 2003;17:1344-55.
30. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997;75:69-75.
31. Ross D, Traver RD, Siegel D, et al. A polymorphism in NAD(P)H: quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 1996;74:995-6.
32. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999;9:113-21.
33. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236:313-22.
34. Jaiswal AK. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med 2000;29:254-62.
35. Pietsch EC, Chan JY, Torti FM, Torti SV. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem 2003;278:2361-9.
36. Tsuji Y, Ayaki H, Whitman SP, et al. Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol 2000;20:5818-27.
37. Bosio A, Knorr C, Janssen U, et al. Kinetics of gene expression profilingin Swiss 3T3 cells exposed to aqueous extracts of cigarette smoke. Carcinogenesis 2002;23:741-8.
38. Chan JY, Kwong M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim Biophys Acta 2000;1517:19-26.
39. Ramos-Gomez M, Kwak MK, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 2001;98:3410-5.
40. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
41. Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res 2000;86:347-54.
42. Kanner J, Harel S, Granit R. Nitric oxide as an antioxidant. Arch Biochem Biophys 1991;289:130-6.
43. Gorbunov NV, Yalowich JC, Gaddam A, et al. Nitric oxide prevents oxidative damage produced by tert-butyl hydroperoxide in erythroleukemia cells via nitrosylation of heme and non-heme iron. Electron paramagnetic resonance evidence. J Biol Chem 1997;272:12328-41.
44. Loibl S, von Minckwitz G, Weber S, et al. Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide usinge lectron paramagnetic resonance spectroscopy. Cancer 2002;95:1191-8.
45. Vakkala M, Paakko P, Soini Y. eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. Int J Oncol 2000;17:667-71.
46. Martin JH, Begum S, Alalami O, Harrison A, Scott KW. Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumour Biol 2000;21:90-7.
47. Martin JH, Alalami O, van den Berg HW. Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence. Cancer Lett 1999;144:65-74.
48. Yoshimura M, Yasue H, Nakayama M, et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998;103:65-9.
49. Tesauro M, Thompson WC, Rogliani P, et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A 2000;97:2832-5.
50. Veldman BA, Spiering W, Doevendans PA, et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002;20:2023-7.
51. Choi AM, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lunginjury. Am J Respir Cell Mol Biol 1996;15:9-19.
52. Stocker R. Induction of haem oxygenase as a defence against oxidative stress. Free Radic Res Commun 1990;9:101-12.
53. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997;37:517-54.
54. Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci U S A 1989;86:99-103.
55. Cantoni L, Rossi C, Rizzardini M, Gadina M, Ghezzi P. Interleukin-1 and tumour necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids. Biochem J 1991;279:891-4.
56. Terry CM, Clikeman JA, Hoidal JR, Callahan KS. Effect of tumor necrosis factor-a and interleukin-1a on heme oxygenase-1 expression in human endothelial cells. Am J Physiol 1998;274:H883-91.
57. Favatier F, Polla BS. Tobacco-smoke-inducible human haem oxygenase-1 gene expression: role of distinct transcription factors and reactive oxygen intermediates. Biochem J 2001;353:475-82.
58. Yoshida T, Biro P, Cohen T, Muller RM, Shibahara S. Human heme oxygenase cDNA and induction of its mRNA by hemin. Eur J Biochem 1988;171:457-61.
59. Doi K, Akaike T, Fujii S, et al. Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer 1999;80:1945-54.
60. Goodman AI, Choudhury M, da Silva JL, Schwartzman ML, Abraham NG. Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc Soc Exp Biol Med 1997;214:54-61.
61. Yachie A, Niida Y, Wada T, et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 1999;103:129-35.
62. Kimpara T, Takeda A, Watanabe K, et al. Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson disease. Hum Genet 1997;100:145-7.
63. Yamada N, Yamaya M, Okinaga S, et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000;66:187-95.
64. Schillinger M, Exner M, Mlekusch W, et al. Heme oxygenase-1 genotype is a vascular anti-inflammatory factor following balloon angioplasty. J Endovasc Ther 2002;9:385-94.
65. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002;94:2490-501.
66. Bergmann MM, Calle EE, Mervis CA, et al. Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol 1998;147:556-62.
67. Rothman KJ, Greenland S. Modern epidemiology. 2nd edition. Baltimore: Lippincott, Williams and Wilkins; 1998.
68. Block G, Hartman AM, Naughton D. A reduced dietary questionnaire: development and validation. Epidemiology 1990;1:58-64.
69. Block G, Coyl L, Smucker R, Harlan L. Health Habits and History Questionnaire: diet history and other risk factors [personal computer system documentation]. Bethesda (MD): Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health; 1989.
70. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 1997;65:1220-8S.
71. Flagg EW, Coates RJ, Calle EE, Potischman N, Thun MJ. Validation of the American Cancer Society Cancer Prevention Study II Nutrition Survey Cohort Food Frequency Questionnaire. Epidemiology 2000;11:462-8.
72. Sherry ST, Ward M, Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 1999;9:677-9.
73. Siegelmann-Danieli N, Buetow KH. Significance of genetic variation at the glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase 1 detoxification genes in breast cancer development. Oncology 2002;62:39-45.
74. Menzel HJ, Sarmanova J, Soucek P, et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 2004;90:1989-94.
75. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001;11:719-25.
76. Cai H, Wilcken DE, Wang XL . The Glu-298!Asp (894G!T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease. J Mol Med 1999;77:511-4.
77. Worda C, Walch K, Sator M, et al. The influence of Nos3 polymorphisms on age at menarche and natural menopause. Maturitas 2004;49:157-62.
78. Yang J, Ambrosone CB, Hong CC, et al. Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking, and risk of postmenopausal breast cancer. Carcinogenesis 2007;28:1247-53.
79. Feigelson HS, Jonas CR, Robertson AS, et al. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2003;12:161-4.
80. Ziegler RG, Hoover RN, Nomura AM, et al. Relative weight, weight change, height, and breast cancer risk in Asian-American women. J Natl Cancer Inst 1996;88:650-60.
81. Rebbeck TR. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 1999;86:2493-501.
82. Liu JM, Hankinson SE, Stampfer MJ, et al. Body iron stores and their determinants in healthy postmenopausal US women. Am J Clin Nutr 2003;78:1160-7.
83. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
84. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006;78:464-79.
85. Johnson N, Fletcher O, Palles C, et al. Countingpotenti ally functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 2007;16:1051-7.
86. Fowke JH, Shu XO, Dai Q, et al. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2004;13:1308-15.
87. Hamajima N, Matsuo K, Iwata H, et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 2002;7:103-8.
88. Ghilardi G, Biondi ML, Cecchini F, et al. Vascular invasion in human breast cancer is correlated to T!786C polymorphism of NOS3 gene. Nitric Oxide 2003;9:118-22.
89. Royo JL, Moreno-Nogueira JA, Galan JJ, et al. Lack of association between NOS3 Glu298Asp and breast cancer risk: a case-control study. Breast Cancer Res Treat 2006;100:331-3.
90. Sarmanova J, Susova S, Gut I, et al. Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet 2004;12:848-54.
91. Hefler LA, Grimm C, Lantzsch T, et al. Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat 2006;98:151-5.
92. Cade J, Thomas E, Vail A. Case-control study of breast cancer in south east England: nutritional factors. J Epidemiol Community Health 1998;52:105-10.
93. Kikuchi A, Yamaya M, Suzuki S, et al. Association of susceptibility to the development of lungadenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. Hum Genet 2005;116:354-60.
94. Chang KW, Lee TC, Yeh WI, et al. Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurringon male areca chewers. Br J Cancer 2004;91:1551-5.
95. Bauer M, Bauer I. Heme oxygenase-1: redox regulation and role in the hepatic response to oxidative stress. Antioxid Redox Signal 2002;4:749-58.
96. Vile GF, Tyrrell RM. Oxidative stress resultingfrom ultraviolet A irradiation of human skin fibroblasts leads to a heme oxygenasedependent increase in ferritin. J Biol Chem 1993;268:14678-81.
97. Turkseven S, Kruger A, Mingone CJ, et al. Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes. Am J Physiol Heart Circ Physiol 2005;289:H701-7.
98. Farhangkhoee H, Khan ZA, Mukherjee S, et al. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 2003;35:1439-48.
99. Foresti R, Motterlini R. The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. Free Radic Res 1999;31:459-75.
100. Chen S, Khan ZA, Barbin Y, Chakrabarti S. Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic Res 2004;38:1301-10.
101. Noguchi M, Yoshida T, Kikuchi G. A stoichiometric study of heme degradation catalyzed by the reconstituted heme oxygenase system with special consideration of the production of hydrogen peroxide duringthe reaction. J Biochem (Tokyo) 1983;93:1027-36.
102. Okamoto I, Krogler J, Endler G, et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. Int J Cancer 2006;119:1312-5.
103. Mainous AG III, Gill JM, Everett CJ. Transferrin saturation, dietary iron intake, and risk of cancer. Ann Fam Med 2005;3:131-7.
104. Patel AV, Calle EE, Pavluck AL, et al. A prospective study of XRCC1 (X-ray cross-complementingg roup 1) polymorphisms and breast cancer risk. Breast Cancer Res 2005;7:R1168-73.
105. Meek PM, Nail LM, Barsevick A, et al. Psychometric testingof fatigue instruments for use with cancer patients. Nurs Res 2000;49:181-90.
106. Jensen OM, Wahrendorf J, Rosenqvist A, Geser A. The reliability of questionnaire-derived historical dietary information and temporal stability of food habits in individuals. Am J Epidemiol 1984;120:281-90.